Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of haematuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs other supportive care treatment Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Tonsillectomy plus standard care vs standard care Death (any cause) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Tonsillectomy plus standard care vs standard care Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Tonsillectomy plus standard care vs standard care > 50% increase in SCr · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs placebo or no treatment Remission of haematuria · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs placebo or no treatment Relapse of proteinuria · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs placebo or no treatment > 50% increase in SCr · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Renin‐angiotensin system inhibition vs other supportive care treatment Death · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane | no estimate extracted | NR | No studies |
Evening vs morning dosing regimen Cardiovascular mortality (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | no estimate extracted | NR | No studies |
Evening vs morning dosing regimen Cardiovascular morbidity (stroke, myocardial infarction, congestive heart failure, aortic aneurysm) (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane | no estimate extracted | NR | No studies |
Magnesium sulphate vs placebo (outcomes Breastfeeding at hospital discharge** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane | no estimate extracted | NR | No studies |
Magnesium sulphate vs placebo (outcomes Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation) Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Early graft loss ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Delayed graft function ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Acute rejection ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Ureteric complications ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Laparoscopic vs hand‐assisted Kidney function at one year ‐ not reported · live donor nephrectomy (secondary outcomes) Robotic versus laparoscopic versus open nephrectomy for live kidney donors (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer paste (autolytic) vs 10% aqueous polyvinylpyrrolidone Proportion of wounds completely healed · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer paste (autolytic) vs 10% aqueous polyvinylpyrrolidone Time to complete healing (days) · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer paste (autolytic) vs 0.1% chloramine‐soaked dressings Proportion of wounds completely debrided · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer paste (autolytic) vs 0.1% chloramine‐soaked dressings Rate of reduction in wound size · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer paste (autolytic) vs 0.1% chloramine‐soaked dressings Proportion of wounds completely healed · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs silicone foam elastomer (autolytic) Time to a clean wound bed · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs Eusol gauze Proportion of wounds completely debrided · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs silicone foam elastomer (autolytic) Proportion of wounds completely debrided · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs silicone foam elastomer (autolytic) Rate of reduction in wound size · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs silicone foam elastomer (autolytic) Proportion of wounds completely healed · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs silicone foam elastomer (autolytic) Serious adverse events: life‐threatening/ hospitalisation · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Streptokinase/streptodornase (enzymatic) vs saline‐soaked dressing Proportion of wounds completely debrided · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Streptokinase/streptodornase (enzymatic) vs saline‐soaked dressing Rate of reduction in wound size · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Streptokinase/streptodornase (enzymatic) vs saline‐soaked dressing Proportion of wounds completely healed · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Streptokinase/streptodornase (enzymatic) vs saline‐soaked dressing Time to complete healing (days) · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs Eusol gauze Rate of reduction in wound size · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical debridement via an endoscopic method vs conventional 'open' surgical debridement Proportion of wounds completely debrided · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical debridement via an endoscopic method vs conventional 'open' surgical debridement Rate of reduction in wound size · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical debridement via an endoscopic method vs conventional 'open' surgical debridement Proportion of wounds completely healed · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Surgical debridement via an endoscopic method vs conventional 'open' surgical debridement Serious adverse events: life‐threatening/ hospitalisation · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs Eusol gauze Proportion of wounds completely healed · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs Eusol gauze Time to complete healing (days) · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer beads (autolytic) vs Eusol gauze Serious adverse events: life‐threatening/ hospitalisation · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer paste (autolytic) vs 10% aqueous polyvinylpyrrolidone Proportion of wounds completely debrided · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dextranomer paste (autolytic) vs 10% aqueous polyvinylpyrrolidone Rate of reduction in wound size · adults with surgical wounds Debridement for surgical wounds (2024) · Cochrane | no estimate extracted | NR | No studies |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Doubling of SCr · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Fatal or nonfatal stroke · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Dual therapy (angiotensin‐converting‐enzyme inhibitors plus angiotensin receptor blockers) vs placebo or no treatment Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Doubling of SCr · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Fatal or nonfatal stroke · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting‐enzyme inhibitors (ACEi) vs another ACEi Micro‐ to macroalbuminuria · people with diabetes and kidney disease Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane | no estimate extracted | NR | No studies |